Foreign firms reap 60% of China's healthcare stimulus

Experts on China have a cautionary bit of advice for drugmakers: The devil is in the details. On a top-line basis, China's pledge of a $125 billion investment in healthcare this year looks great. In reality, consumption is growing so fast that spending can't keep up--and that means an increasing squeeze on costs.

For reasons both political and economic, the Chinese government wants to provide higher-quality healthcare that's also more efficient, the Asia Times reports. That means "increasingly aggressive cost saving plans" aimed at controlling expenses. Witness the across-the-board price cuts on some key drugs last year, for instance. We've reported on the "Anhui Model" before, but it bears repeating: That province's centralized tender process, which puts a major damper on prices, has been replicated by more than a dozen other provinces.

But that doesn't mean pharma can't prosper in China. Good thing, since drug companies have been placing big bets on the Chinese market, building R&D and manufacturing facilities worth hundreds of millions, plus hiring hordes of sales reps. A clutch of drugmakers -- AstraZeneca ($AZN), Sanofi ($SNY), Roche ($RHHBY), GlaxoSmithKline ($GSK), Novo Nordisk ($NVO), Johnson & Johnson ($JNJ) and Pfizer ($PFE)--all saw 30%-plus growth in China in early 2011, J.P. Morgan says.

One contributing factor? As Kleiner Perkins managing director James Huang said at OneMedPlace's China Forum in San Francisco, some 60% of China's healthcare stimulus money "ended up going to non-Chinese multinationals." Big Pharma included.

- read the Asia Times piece

Suggested Articles

Having only just completed an expansion in Illinois, PCI Pharma Services will now expand its solid dose facility in Wales in the U.K.

With a green light in lung cancer, AstraZeneca's Imfinzi has become the first PD-L1 drug approved in China, ahead of Roche's Tecentriq.

The FDA has come down on a small U.S. drugmaker for taking a skin medication to market even though there were out-of-spec test results at release.